What is AstraZeneca Pharma India Book Value per Share?
AstraZeneca Pharma India's book value per share for the quarter that ended in Dec. 2024 was ₹0.00.
During the past 12 months, AstraZeneca Pharma India's average Book Value Per Share Growth Rate was 3.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 16.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 18.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 16.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of AstraZeneca Pharma India was 26.80% per year. The lowest was -11.60% per year. And the median was 14.95% per year.
During the past 13 years, the highest P/B Ratio of AstraZeneca Pharma India was 28.87. The lowest was 9.76. And the median was 16.10.
Warning Sign:
AstraZeneca Pharma India Ltd stock PB Ratio (=28.85) is close to 10-year high of 28.85.
AstraZeneca Pharma India Book Value per Share Historical Data
The historical data trend for AstraZeneca Pharma India's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
AstraZeneca Pharma India Book Value per Share Chart
Competitive Comparison of AstraZeneca Pharma India's Book Value per Share
For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AstraZeneca Pharma India's PB Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's PB Ratio distribution charts can be found below:
* The bar in red indicates where AstraZeneca Pharma India's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
AstraZeneca Pharma India (BOM:506820) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
AstraZeneca Pharma India Book Value per Share Related Terms
Thank you for viewing the detailed overview of AstraZeneca Pharma India's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BOM:506820 has been successfully added to your 